ArticleJACC. Case reports2026
Transcatheter Tricuspid Valve Replacement for Torrential Tricuspid Regurgitation in Complex Adult Congenital Heart Disease.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere tricuspid regurgitation (TR) carries high morbidity and is often undertreated in patients with complex congenital heart disease and prohibitive surgical risk. CASE SUMMARY: A 33-year-old woman with complex congenital heart disease and multiple prior surgeries presented with progressive right-sided heart failure and torrential TR. Imaging demonstrated septal leaflet splinting by a transvenous pacing lead. She was unsuitable for surgery or transcatheter edge-to-edge repair. Following Heart Team assessment, transcatheter tricuspid valve replacement with a 48 mm EVOQUE valve (Edwards Lifesciences) was performed. Despite procedural challenges including delivery system septal bias, implantation was successful with mild residual TR and early symptomatic improvement. DISCUSSION: Transcatheter tricuspid valve replacement is an emerging option for high-risk patients. This case demonstrates feasibility in complex congenital anatomy with pacing leads, a group under-represented in current evidence. TAKE-HOME MESSAGES: Transcatheter tricuspid valve replacement expands treatment options in high-risk congenital tricuspid regurgitation. Careful imaging and Heart Team planning are essential for success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.